A multi-centre, open-label, randomised, controlled trial to show whether in patients with K-RAS wild-type tumours the addition of panitumumab to irinotecan (IrPan), gives superior anti-cancer efficacy compared to standard irinotecan alone (Ir), and whether (regardless of tumour subtype) the modulation of irinotecan with ciclosporin (IrCs) offers non-inferior anti-cancer efficacy and reduced toxicity compared to Ir. The required sample size is 1324 patients.
Trial Status: Published
Chief Investigator: Professor Matt Seymour, St James's University Hospital
Julie Croft, Emma Best, Matthew Potton
|PICCOLO Protocol||353.81 KB|